Glucose Laboratoire Aguettant (Glucose Monohydrate)

Glucose Laboratoire Aguettant is used in clinical settings where rapid provision of an energy substrate is required.

• To correct or prevent low blood glucose levels (hypoglycemia) in patients who cannot eat or absorb carbohydrates.
• As part of intravenous fluid therapy to maintain caloric intake during surgery or intensive care.
• To supply glucose for patients receiving parenteral nutrition when oral intake is insufficient.
• In diagnostic procedures such as glucose tolerance testing where controlled glucose administration is needed.
• To support metabolic demands in patients with increased energy requirements, such as trauma or severe infection.

Adverse reactions to Glucose Laboratoire Aguettant are generally related to the intravenous administration of a carbohydrate solution.

Common

• Mild nausea or vomiting.
• Transient headache or dizziness.
• Local irritation at the infusion site, such as erythema or mild pain.
• Temporary increase in thirst due to higher osmolality.
• Slight rise in serum potassium levels.

Serious

• Hyperglycemia with markedly elevated blood glucose.
• Fluid overload or pulmonary edema, especially in patients with cardiac or renal impairment.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Electrolyte disturbances, for example hyponatremia or severe potassium shifts.
• Osmotic diuresis leading to dehydration and electrolyte loss.

When using Glucose Laboratoire Aguettant, clinicians should consider several precautionary measures to ensure safe administration and to minimize risk.

• Assess blood glucose before and during infusion to avoid hyperglycemia.
• Evaluate fluid status and cardiac function, especially in patients at risk of volume overload.
• Use aseptic technique to prevent contamination of the intravenous solution.
• Adjust infusion rate in patients with renal or hepatic impairment.
• Monitor electrolytes, particularly sodium and potassium, during prolonged therapy.
• Consider alternative carbohydrate sources for patients with known glucose intolerance or metabolic disorders.

Glucose Laboratoire Aguettant may interact with other medications or clinical conditions; awareness of these interactions helps guide appropriate use.

Avoid

• Concurrent administration of high‑dose insulin without glucose monitoring, which can precipitate severe hypoglycemia.
• Co‑infusion with hypertonic saline solutions that could exacerbate fluid overload.
• Use in patients receiving diuretics that markedly alter electrolyte balance without close monitoring.

Use with caution

• Concurrent use of potassium‑containing IV fluids, as glucose infusion can shift potassium intracellularly.
• Administration alongside beta‑adrenergic agonists, which may increase glucose production and affect blood sugar control.
• Patients on corticosteroids, who may have altered glucose metabolism, requiring closer glucose monitoring.